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Differences in genomic abnormalities
among African individuals with
monoclonal gammopathies using
calculated ancestry
Linda B. Baughn1, Kathryn Pearce1, Dirk Larson2, Mei-Yin Polley2, Eran Elhaik3, Michael Baird4, Colin Colby2,
Joanne Benson2, Zhuo Li5, Yan Asmann5, Terry Therneau2, James R. Cerhan 2, Celine M. Vachon2, A. Keith Stewart6,7,
P. Leif Bergsagel 6, Angela Dispenzieri7, Shaji Kumar 7 and S. Vincent Rajkumar7
Abstract
Multiple myeloma (MM) is two- to three-fold more common in African Americans (AAs) compared to European
Americans (EAs). This striking disparity, one of the highest of any cancer, may be due to underlying genetic
predisposition between these groups. There are multiple unique cytogenetic subtypes of MM, and it is likely that the
disparity is associated with only certain subtypes. Previous efforts to understand this disparity have relied on self-
reported race rather than genetic ancestry, which may result in bias. To mitigate these difﬁculties, we studied 881
patients with monoclonal gammopathies who had undergone uniform testing to identify primary cytogenetic
abnormalities. DNA from bone marrow samples was genotyped on the Precision Medicine Research Array and
biogeographical ancestry was quantitatively assessed using the Geographic Population Structure Origins tool. The
probability of having one of three speciﬁc subtypes, namely t(11;14), t(14;16), or t(14;20) was signiﬁcantly higher in the
120 individuals with highest African ancestry (≥80%) compared with the 235 individuals with lowest African ancestry
(<0.1%) (51% vs. 33%, respectively, p value= 0.008). Using quantitatively measured African ancestry, we demonstrate a
major proportion of the racial disparity in MM is driven by disparity in the occurrence of the t(11;14), t(14;16), and t
(14;20) types of MM.
Introduction
Monoclonal gammopathies, such as multiple myeloma
(MM), represent a collection of plasma cell (PC) neo-
plasms comprised of mostly incurable hematopoietic
malignancies with an increasing incidence (~6 cases per
100,000 individuals during 2008–2012) in the United
States1,2. MM is the most common hematologic malig-
nancy in African Americans (AAs). AAs have a 2–3-fold
higher prevalence of monoclonal gammopathy of unde-
termined signiﬁcance (MGUS) and a similarly higher
incidence of MM, along with a ~4-year younger age of
onset compared to European Americans (EAs)3. The
increased incidence of MM among AAs has been attrib-
uted to the increased prevalence of MGUS, with a similar
risk of MGUS to MM progression between EAs and AAs3.
Increased MGUS prevalence cannot be fully explained by
environmental differences between AAs and EAs in the
US, since West African Ghanaian men also display
increased prevalence of MGUS4. The combined observa-
tions that MGUS/MM clusters in families observed by a
2–4-fold increased risk of ﬁrst-degree relatives of MM5–7,
the higher incidence of MGUS among AAs and Western
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Africans and the earlier age of onset of MM in AAs
suggest an ancestral-associated genetic predisposition to
developing MM8. Further, when access to care is equal,
AAs have better overall survival compared to EAs, sug-
gesting that AAs may have a genetic predisposition that
renders them better responders to treatment or have
more indolent subtypes of MM9.
MM, although considered a single disease, can be divi-
ded into different cytogenetically deﬁned subtypes with
differences in disease outcome. Cytogenetic subtypes
include hyperdiploidy (characterized by gains of odd-
numbered chromosomes), and translocations involving
the immunoglobulin heavy chain (IgH) gene on chromo-
some 14 with partner chromosomes resulting most
commonly in t(11;14), t(4;14), t(14;16) and more rarely
IgH translocations involving t(6;14), and t(14;20). The
primary cytogenetic abnormalities most associated with
standard risk includes hyperdiploidy; t(11;14) or t(6;14)
and high-risk abnormalities are deﬁned as t(4;14), t(14;16)
and t(14;20)10,11. Secondary cytogenetic ﬁndings, includ-
ing gain of chromosome 1q, deletion of 17p, including the
TP53 gene and rearrangements involving the MYC locus
can also inﬂuence disease outcome12. Previous studies
reported that AAs exhibit a lower frequency of IgH
translocations, including reduced t(11;14) and t(4;14) in
some studies, and no signiﬁcant differences in hyperdi-
ploidy were observed13,14. Most of these studies, however,
relied on self-reported race, which is known to be a highly
biased measure rather than genetic ancestry15–17. Lever-
aging ancestry informative single-nucleotide polymorph-
isms (SNPs) allows quantifying one’s genetic ancestry in
an admixture framework. We hypothesize that quantify-
ing genetic ancestry is a necessary component to
fully understand the genetic mechanisms of racial dis-
parities of monoclonal gammopathies. In this study, we
utilized genotyping data to calculate individual ancestry
and examined whether primary and secondary cytoge-
netic abnormalities differed by high and low African
ancestry.
Materials and Methods
Sample eligibility
Samples for this study were obtained from the Mayo
Clinic Genomics Laboratory after obtaining Institutional
Review Board approval. A retrospective cohort of
1000 specimens were identiﬁed from patients who had an
abnormal plasma cell proliferative disorder ﬂuorescence
in situ hybridization (FISH) result and a concurrent
conventional G-banded chromosome evaluation as part of
routine clinical testing. The abnormal plasma cell FISH
result along with patient age at the time of clinical cyto-
genetic testing, gender and self-reported race (if available)
were also recorded.
Fluorescence in situ hybridization (FISH) analysis
Plasma cell proliferative disorder FISH of immunoglo-
bulin (cIg)-stained positive PCs studies were performed as
part of routine clinical testing using the following probes:
RB1/LAMP1 (Abbott Molecular, Des Plains, IL, USA) for
monosomy 13 or 13q deletion, TP53/D17Z1 (Abbott
Molecular) for TP53 deletion or monosomy 17, D3Z1/
D7Z1/D9Z1/D15Z4 (Abbott Molecular) for trisomy 3, 7,
9 or 15, TP73/1q22 (custom probe) for 1q gain, MYC
(Abbott Molecular) for 8q24.1 rearrangement, IgH (cus-
tom probe) for 14q32 rearrangements and probes tar-
geting individual IGH rearrangement detecting t(11;14)
(q13;q32) CCND1/IgH (Abbott Molecular), t(4;14)(p16.3;
q32) FGFR3/IgH (Abbott Molecular), t(6;14)(p21;q32)
CCND3/IgH (custom probe), t(14;16)(q32;q23) IgH/MAF
(Abbott Molecular), and t(14;20)(q32;q12) IgH/MAFB
(custom probe). Deletion or monosomy of chromosomes
13 and 17 and copy number gain of 1q were detected
using enumeration strategy probes. Centromere probes
were used to detect chromosomal aneusomy of chromo-
somes 3, 7, 9, and 15. Translocations involving IgH with
FGFR3, CCND1, CCND3, MAF, andMAFB were detected
using dual-color, dual-fusion (D-FISH) strategy probes
and rearrangements of IgH and MYC were detected using
a break-apart strategy (BAP) probe. Plasma cells were
identiﬁed using immunoglobulin staining techniques
using antibodies targeting cytoplasmic immunoglobulin
kappa and lambda. For each probe set, 50 plasma cells (if
possible) were scored and the result for each probe was
reported.
Chromosome analysis
A conventional G-banded chromosome evaluation was
performed as part of routine clinical testing. First, a cell
count is performed on the specimen to establish a plating
volume and based on the cell count, a corresponding
volume of bone marrow is added to 2 culture ﬂasks
containing culture medium and incubated for 24 to 48 h
at 37 degrees C. In the harvest process, the cells are
exposed to colcemid and hypotonic solution, and are ﬁxed
with glacial acid and methanol. Metaphase cells are
dropped onto microscope slides and are stained by G-
banding and twenty metaphases are usually examined.
Minimal evidence for the presence of an abnormal clone
is deﬁned as 2 or more metaphases with the same struc-
tural abnormality or chromosome gain (trisomy), or 3 or
more metaphases lacking the same chromosome. All cells
analyzed are captured using a computerized imaging
system, and 1 or more karyograms from each clone are
prepared to document the type of abnormality and to
permit systematic interpretation of the anomalies. For the
purpose of this study, loss of the Y chromosome and
presumed constitutional abnormalities such as inv(2)
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Table 1 Regional ancestries or admixture components employed by the GPSO algorithm
Regional ancestry Description
Africa
1 South African Bushmen Localized to South Africa
2 African Pygmies Associated with the Pygmy people
3 South western Africa Peaks in Nigeria and declines in Senegal, Gambia, and Kenya
4 Hadza Peaks in Tanzania
5 Madagascar Peaks in Madagascar with residues in South Africa
6 Western Ethiopia Peaks in Western Ethiopia and south Sudan
7 Northwestern Africa Peaks in Algeria and declines in Morocco and Tunisia
8 Southern Ethiopia South Ethiopia
9 South Africa Peaks in Botswana, Namibia, Anglola, and with residues in South Africa
10 West Africa Peaks in Senegal and Gambia and declines in Algeria and Morocco
Native America
11 Central America Peaks in Mexico and Central America with resides in Greenland, Peru, Siberia, and east Russia
12 Eastern Amazon Associated with the Surui people in Brazil. Declines in Colombia
13 Pima County Peaks in Central-North America and declines towards Greenland and Eskimos
14 Western Amazon Peaks in endemic to the Karitiana people (Brazil) and declines in Colombia
15 Southeastern America Peaks in Peru, Mexico, and North America and declines in Eastern Russia
India
16 Northern India Peaks in North India (Dharkars, Kanjars) and declines in Pakistan
17 Southeastern India South eastern India with residues in Pakistan
18 Southwestern India Peaks in Pulayar Indian with residues in Paniya, Savara, Bengali, Juang, Savara, Ho, Bonda
Indian
Southeast Asia
19 South China Peaks in Taiwan and Malay and declines in Thailand, Vietnam, Cambodia, and South China
20 South Eastern Asia Peaks in East Asia, Central-south China (Lahu, Naxi, Yi) and declines towards India
21 Central Southern China: Yunnan and Guangxi Peaks in East Asia (East) and Chinese (She, Dai) with residues in Central south China (Han,
Miao, Tujia)
22 North eastern Oceania Peaks in Korea, Chinese (Han), Mynamar, Japan, and Vietnam and declines towards west
China and India
Northeast Asia
23 Japan Peaks in Japan
24 Northeastern China Peaks in East Asia and North East and declines in North east Russia and Siberia
25 North Mongolia Peaks in north Mongolia and declines in Siberia
Oceana
26 Bougainville Peaks in Bougainville and declines in Australia
27 Papuan New Guinea Peaks in Papua New Guinea and declines in Australia
Northern Europe
28 Fennoscandia Peaks in the Iceland and Norway and declines in Finland, England, and France
29 Orkney Islands Peaks in the Orkney islands and declines in England, France, Germany, Belarus, and Poland
Mediterranean
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(p11.2q13) were interpreted as a normal result. A portion
of the cell culture pellet is ﬁxed in methanol/acetic acid
for storage.
DNA extraction and PMRA genotyping
DNA was isolated from ﬁxed cell pellets from residual
chromosome studies that yielded normal results using the
DNeasy Blood and Tissue Kit (Qiagen, Germantown, MD,
USA) following the manufacturer’s recommended proto-
col. DNA was quantitated using a Qubit Fluorometric
Quantitation Instrument (Thermo Fisher Scientiﬁc,
Waltham, MA, USA) and 100 ng of DNA (5 ng/μL) was
used for genotyping on a 96-well Axiom array manu-
factured by Affymetrix (Thermo Fisher Scientiﬁc), the
Precision Medicine Research Array (PMRA) (https://
www.thermoﬁsher.com/order/catalog/product/902981)
comprised of ~730,000 autosomal single-nucleotide
polymorphisms (SNPs), following the manufacturer’s
recommended protocol. A negative and two positive
controls (Coriell samples) were included on each run.
Data were analyzed by the Affymetrix Axiom Analysis
Software Suite to determine genotypes with a required
call rate threshold of at least 99%. The data from auto-
somal markers were analyzed by the GPS Origins Soft-
ware (https://homedna.com/ancestry/gps-origins) to
generate the ethnic breakdown of each sample.
Biogeographical inference
Biogeographical analyses were carried out using the
commercial Geographic Population Structure Origins
(GPSO) tool provided by the DNA Diagnostics Center.
GPSO works similarly to the GPS tool18–20, which cal-
culates the ancestry of an individual in relation to nine
putative ancestral populations representing geographic
regions (e.g., South Africa) and outputs admixture pro-
portions corresponding to those ancestries19. GPSO
expands the original GPS model by inferring ancestry
using 36 admixture proportions (Table 1) and was used to
elucidate the African and non-African ancestries of each
sample from the PMRA genotype data. The ancestry of
the 881 samples was calculated by applying the GPSO to
the SNP data genotyped on the Precision Medical
Research Array (PMRA). GPSO provided an ancestral
breakdown of 36 admixture components for each indivi-
dual representing different geographic regions (Table 1).
African ancestry was calculated by summing the ten
ancestral African components (Table 1, populations
1–10) and European ancestry was similarly calculated
using seven admixture components associated with
Northern Europe and the Mediterranean (populations
28–34) (Table 1).
Statistical analysis and calculation of odds ratios
The analysis focused on examining the associations
between the genetic abnormalities and African ancestry.
The latter was examined as both a continuous variable
(percentage of African genetics) and a categorical variable
(primarily African descent, primarily European descent,
and other). First, the association of the various genetic
abnormalities and African ancestry (continuous) was
examined using logistic regression in a generalized addi-
tive model; odds ratio estimates (and 95% conﬁdence
intervals) associated with 10% increase in African genetics
were estimated. Smoothing spline was used to visualize
the relationship between percentage of African genetics
and probability of genetic abnormalities. Patients were
also divided into 3 ancestral categories: African descent=
at least 80% African ancestry; European descent= less
than 0.1% African ancestry and <30% Asian ancestry;
Other= all other genetic backgrounds; and the associa-
tion of these categories with demographic factors and
genetic abnormalities were evaluated using chi-square
tests. Where appropriate, p values were adjusted using the
Benjamini-Hochberg procedure to control the false dis-
covery rate. All analyses were performed using R version
3.4.2.
Table 1 continued
Regional ancestry Description
30 Arabia Peaks in Saudi Arabia and Yemen and declines in Israel, Jordan, Iraq, and Egypt
31 Basque Country Peaks in France and Spain Basque regions and declines in Spain, Sweden, France, and
Germany
32 Sardinia Peaks in Sardinia and declines in Italy, Greece, Albania, and The Balkans
33 Southern France Peaks in south France and declines in France, England, Orkney islands, and Scandinavia
34 Eastern Mediterranean Peaks in Israel with residues in Syria
Siberia
35 Western Siberia Peaks in Krasnoyarsk Krai and declines towards east Russia
36 East Russia Peaks in South Siberia (Russians: Tuvinian) and declines in North Mongolia
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Results
Patient cohort
Of the 1000 samples eligible for this study, genotype and
ancestry data were obtained from 881 independent sam-
ples. All 881 samples had an abnormal plasma cell FISH
result and had either a normal (N= 851) or abnormal (N
= 30) chromosome study. The median age for the entire
cohort at the time of cytogenetic testing was 64 years
(range 26–90 years) with the highest proportion of indi-
viduals (35.4%) in the 60–69 age category. There were 478
males (54.3%) and 403 females (45.7%) with no signiﬁcant
difference in the proportion of primary cytogenetic
abnormalities observed between males and females (Table
2). From the 881 samples, self-reported race was available
from 393 individuals and 161 self-reported as African
(including African American, Black or Caribbean black)
and 185 self-reported as non-Hispanic Caucasian. Of the
remaining 47 individuals from the self-reported cohort, 35
individuals identiﬁed as Asian, nine as Caucasian with
Hispanic ethnicity, two as Native American and one self-
reported with unknown ancestry. Self-reported ancestry
information was not available from the remaining 488
individuals.
Characterization of genetic ancestry
We ﬁrst compared the calculated ancestry data to the
self-reported ancestry information in the 393 individuals
described above (Fig. 1). Of the 185 self-reported non-
Hispanic Caucasian individuals, the median European
ancestry was 68.2% (mean 67.9%, range 45.1–82.8%)
[median Northern European 33.1% (mean 31.9%, range
15.8–44.5%)]. One self-reported Caucasian individual
(omitted from the range calculation) had <0.1% European
ancestry with 85.5% Asian ancestry. The median African
admixture in the self-reported non-Hispanic Caucasian
population was 0.30% (mean 1.6%, range 0–31.6%). Nearly
Table 2 Demographics by ancestry and cytogenetic abnormalities by gender
African descent (N= 120) European descent (N= 235) Other (N= 526) Total (N= 881) p value
Demographics by ancestry
Gender 0.028
Female 68 (56.7%) 99 (42.1%) 236 (44.9%) 403 (45.7%)
Male 52 (43.3%) 136 (57.9%) 290 (55.1%) 478 (54.3%)
Age group 0.096
<40 5 (4.2%) 3 (1.3%) 13 (2.5%) 21 (2.4%)
40–49 8 (6.7%) 13 (5.5%) 50 (9.5%) 71 (8.1%)
50–59 32 (26.7%) 57 (24.3%) 138 (26.2%) 227 (25.8%)
60–69 47 (39.2%) 79 (33.6%) 186 (35.4%) 312 (35.4%)
70–79 19 (15.8%) 69 (29.4%) 107 (20.3%) 195 (22.1%)
80+ 9 (7.5%) 14 (6.0%) 32 (6.1%) 55 (6.2%)
Female (N= 403) Male (N= 478) Total (N= 881) p value
Abnormality by gender
Abnormality
t(11;14), t(14;16), or t(14;20) 135 (33.5%) 183 (38.3%) 318 (36.1%) 0.509
t(4;14) 39 (9.7%) 33 (6.9%) 72 (8.2%) 0.509
t(6;14) 7 (1.7%) 7 (1.5%) 14 (1.6%) 0.848
Other IgH 38 (9.4%) 48 (10.0%) 86 (9.8%)
0.848≥≥ Trisomy no IgH 157 (39.0%) 180 (37.7%) 337
(38.3%)
0.848
All Other 27 (6.7%) 27 (5.6%) 54 (6.1%) 0.848
P values are based on the comparison of the indicated abnormality (versus otherwise) compared to individuals ≥80.0% African ancestry, individuals with <0.1%
African (excluding Asian ancestry) and all others individuals (3-group test, top table) and also to gender (bottom table) and are adjusted to control the false discovery
rate (FDR) using the method of Benjamini and Hochberg
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all of those self-reporting as Caucasian (98.9%) had 8.6%
or less African ancestry with the exception of two indi-
viduals with African ancestry of 14.8% and 31.6%. Of the
161 self-reported African individuals, the median African
ancestry was 80% (mean 76.6%, range 15.0–92.2%). A self-
reported African individual with the lowest African
ancestry of 15.0% had 22.6% Native American and 36.2%
European ancestry. The median European admixture in
the self-reported African population was 5.8% (mean
8.8%, range 0–41.9%) [median Northern European 2.7%
(mean 4.2, range 0–25.4%)]. While the range of African
ancestry in individuals self-reporting as African was large,
98.8% of self-reported Africans had at least 30% African
ancestry and 96.9% had at least 50% African ancestry.
Of the entire cohort of 881 individuals, the median
African ancestry was 2.3% (mean 23.5%, range 0–92.2%),
the median European ancestry was 64.7% (mean 47.6%,
range 0–82.8%) and Northern European ancestry was
26.6% (mean 21.8%, range 0–44.5%) (Fig. 1). There were
268 individuals (30.4% of the entire cohort) with <0.1%
African ancestry and 235 of these individuals also had
<30% Asian ancestry representing our non-African and
non-Asian cohort of Caucasian European individuals and
120 individuals (13.6%) had ≥80.0% African ancestry.
Comparison of demographics and cytogenetic
abnormalities using calculated ancestry
The prevalence of demographic variables and cytoge-
netic abnormalities was evaluated with respect to the
percentage of African ancestry in the entire cohort. We
ﬁrst examined whether an increase in the percentage of
African Ancestry altered the odds of any primary cyto-
genetic abnormality. The logistic regression model
demonstrated that a 10% increase in the percentage of
African ancestry was associated with a 6% increase in the
odds of detecting either an t(11;14), t(14;16) or t(14;20)
(odds ratio= 1.06, 95% CI: 1.02–1.11; p value= 0.05)
(Table 3). Since we observed an increase in the prevalence
of each of the individual t(11;14), t(14;16) and t(14;20)
cytogenetic abnormalities with respect to African ancestry
(Table 3), these three abnormalities were combined in
downstream analysis. When we plotted the probability of
observing these cytogenetic abnormalities with respect to
the percentage of African ancestry (Fig. 2), we observed an
increased probability of detecting either an t(11;14), t
(14;16) and t(14;20) as well as reduced probability of
observing an odd numbered trisomy (deﬁned as having a
gain of at least one of the following odd numbered
chromosomes 3, 7, 9, 11, 15 and 17). The differences were
Fig. 1 Percent African ancestry by self-reported race in cohort of
881 individuals. Distribution of the percent of African ancestry based
on the sum of all 10 African regional ancestries within the 881 samples
in this study by self-report race in 393 samples or non-reported race
information in 488 samples
Table 3 Test of increase in the odds of any abnormality
with increasing percent of African Ancestry (AA)
Odds Ratio (95% CI)
associated with 10%
increase in percent of
African Ancestry
FDR adjusted
p value
Trisomy 3 0.98 (0.94, 1.03) 0.542
Trisomy 7 0.97 (0.92, 1.01) 0.272
Trisomy 9 0.99 (0.95, 1.03) 0.542
Trisomy 11 0.96 (0.92, 1) 0.272
Trisomy 13 0.13 (0, 33.45) 0.542
Trisomy 15 0.95 (0.91, 0.99) 0.077
Trisomy 17 1.03 (0.96, 1.1) 0.542
t(4;14) 0.98 (0.91, 1.05) 0.596
t(6;14) 0.94 (0.78, 1.12) 0.542
t(11;14) 1.03 (0.99, 1.08) 0.272
t(14;16) 1.11 (1.02, 1.2) 0.077
t(14;20) 1.10 (0.96, 1.26) 0.272
t(11;14) or t(14;16) or
t(14;20)
1.06 (1.02, 1.11) 0.056
other IgH 0.94 (0.87, 1.01) 0.272
TP53 deletion /
Monosomy 17
0.95 (0.88, 1.01) 0.272
13q deletion or
Monosomy 13
0.97 (0.93, 1.01) 0.272
Any trisomy, no IgH 0.97 (0.93, 1.01) 0.272
MYC rearrangement 0.98 (0.89, 1.08) 0.688
Odds Ratio estimate in the table is associated with 10% increase. Test of
statistical signiﬁcance was based on logistic regression model, with adjustment
of false discovery rate using Benjamini and Hochberg’s procedure (at 0.10 level)
Baughn et al. Blood Cancer Journal  (2018) 8:96 Page 6 of 10
Blood Cancer Journal
most striking in the extreme populations, speciﬁcally
among individuals with ≥80.0% African and individuals
with <0.1% African ancestry (Fig. 2). On the basis of these
results, we further evaluated the proportion of each
cytogenetic abnormality within these most extreme
cohorts with respect to African ancestry; individuals with
≥80.0% African and individuals with <0.1% African
ancestry. A statistically signiﬁcant higher prevalence of t
(11;14), t(14;16) and t(14;20) (p value= 0.008) with a
lower prevalence of trisomies (with or without IgH
translocations) (p value= 0.066) was observed in the
cohort with the greatest proportion of African ancestry
(>80%) compared to the European cohort (≥0.1% African
ancestry) (Table 4). In addition, the >80% African ancestry
cohort also had statistically signiﬁcant lower prevalence of
monosomy 13/13q deletion (p value= 0.021) (Table 5)
and a signiﬁcantly higher prevalence in the proportion of
females with monoclonal gammopathies compared to the
European cohort (p value= 0.028) (Table 2). Similar to
previous studies9,21, we identify an approximate two-fold
reduction in the number of individuals that are ≥80.0%
African compared to individuals with <0.1% African
within the 70–79-age cohort (Table 2).
Discussion
Elucidating the genetic mechanisms of racial disparities
is a fundamental step to understanding the etiology and
improving the detection and clinical outcomes of patients
with monoclonal gammopathies. Here, we complement
from past studies that relied on self-reported race and
characterized the patients’ demographic and uniformly
collected cytogenetic data in relation to genetically
deﬁned African ancestry.
Individuals with the highest African ancestry displayed a
higher prevalence of IgH translocations, t(11;14), t(14;16),
t(14;20), lower prevalence of 13q deletion/monosomy 13
and a trend towards a lower prevalence of trisomy (with
or without IgH translocation) compared to individuals
with the least African ancestry. The differences we
observed were only revealed after analysis of individuals
with the highest and lowest percentage of African
ancestry as no signiﬁcant differences in these variables
were observed when adjusting the cutoff of African
ancestry to >50%, a cutoff that captures approximately
97% of AA individuals from the self-reported cohort (data
not shown). Interestingly, a similar approach that con-
sidered the genetic ancestry of samples from the
Fig. 2 Probability of either t(11;14),t(14;16) or t(14;20) or any trisomy in relation to percent African ancestry. Smoothing spline was used to
visualize the relationship between percentage of African genetics and probability of of t(11;14), t(14;16) or t(14;20) or of any trisomy
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Table 4 Cytogenetic abnormalities by ancestry
African descent (N= 120) European descent (N= 235) Other (N= 526) Total (N= 881) p value
Abnormality by Ancestry
Abnormality
t(11;14), t(14;16), or t(14;20) 61 (50.8%) 77 (32.8%) 180 (34.2%) 318 (36.1%) 0.008
t(4;14) 8 (6.7%) 20 (8.5%) 44 (8.4%) 72 (8.2%) 0.862
t(6;14) 1 (0.8%) 4 (1.7%) 9 (1.7%) 14 (1.6%) 0.862
Other IgH 8 (6.7%) 24 (10.2%) 54 (10.3%) 86 (9.8%) 0.739
Trisomy no IgH 37 (30.8%) 97 (41.3%) 203 (38.6%) 337 (38.3%) 0.464
All Other 5 (4.2%) 13 (5.5%) 36 (6.8%) 54 (6.1%) 0.739
African descent (N= 120) European descent (N= 235) Other (N= 526) Total (N= 881) p value
Trisomy by Ancestry
Any Trisomy 0.066
No Trisomy 62 (51.7%) 91 (38.7%) 229 (43.5%) 382 (43.4%)
Trisomy 58 (48.3%) 144 (61.3%) 297 (56.5%) 499 (56.6%)
P values are based on the comparison of the indicated abnormality (versus otherwise) compared to individuals ≥80.0% African ancestry, individuals with <0.1%
African (excluding Asian ancestry) and all others individuals (3-group test) and are adjusted to control the false discovery rate (FDR) using the method of Benjamini
and Hochberg
Table 5 Progression markers by ancestry
Progression Marker African descent European descent Other Total p value
Progression markers by Ancestry
1q duplication (of 377 tested) 0.576
No 30 (75.0%) 80 (70.8%) 151 (67.4%) 261 (69.2%)
Yes 10 (25.0%) 33 (29.2%) 73 (32.6%) 116 (30.8%)
Total N= 40 N= 113 N= 224 N= 377
17p del/-17 (of 878 tested) 0.087
No 111 (93.3%) 202 (86.3%) 475 (90.5%) 788 (89.7%)
Yes 8 (6.7%) 32 (13.7%) 50 (9.5%) 90 (10.3%)
Total N= 119 N= 234 N= 525 N= 878
13q del/-13 (of 881 tested) 0.021
No 79 (65.8%) 144 (61.3%) 283 (53.8%) 506 (57.4%)
Yes 41 (34.2%) 91 (38.7%) 243 (46.2%) 375 (42.6%)
Total N= 120 N= 235 N= 526 N= 881
MYC rearrangement (of 377 tested) 0.245
No 32 (80.0%) 100 (88.5%) 200 (89.3%) 332 (88.1%)
Yes 8 (20.0%) 13 (11.5%) 24 (10.7%) 45 (11.9%)
Total N= 40 N= 113 N= 224 N= 377
P values are based on the comparison of the indicated abnormality (versus otherwise) compared to individuals ≥80.0% African ancestry, individuals with <0.1%
African (excluding Asian ancestry) and all others individuals (3-group test) and are adjusted to control the false discovery rate (FDR) using the method of Benjamini
and Hochberg
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CoMMpass trial database found that MM tumors from
Africans and Europeans vary in their frequencies of some
common somatic mutated MM genes21. However, these
results were not considered in analyzing the cytogenetic
data and the authors found no signiﬁcant differences
between the proportions of hyperdiploid (deﬁned in their
study as presence of at least three odd-numbered chro-
mosomes) and nonhyperdiploid karyotypes among the
two groups. Approximately 50% of African individuals
with greater than 80% African ancestry have either a t
(11;14), t(14;16) or t(14;20) (Table 4) with the majority of
this category (75%) represented by individuals with t
(11;14) (38.3% of entire ≥80.0% African cohort) (Supple-
mental table 1). As expected, this higher prevalence of t
(11;14) is associated with a lower proportion of cases with
any trisomy (48.3% in ≥80.0% vs. 61.3% in <0.1% African
ancestry; p value= 0.066) (Table 4). Further, individuals
with ≥80% African ancestry also displayed a lower pre-
valence in 17p deletion or monosomy 17 (6.7% in ≥80.0%
vs. 13.7% in 0.1% African ancestry) consistent with the
higher prevalence of t(11;14) and better overall survival
compared to EAs9.
The observation of a higher prevalence of translocations
such as t(11;14), t(14;16) or t(14;20) and no enrichment in
other translocations such as t(4;14) and t(6;14) suggests a
possible predisposition of AAs to the development of
speciﬁc chromosomal rearrangements. Many B-cell
translocations are a result of aberrant B-cell mechan-
isms including VDJ recombination, class switch recom-
bination and somatic hypermutation mediated by
mistargeted RAG1/2 or activation induced cytidine dea-
minase (AID) enzymes22. In myeloma, most 14q32
breakpoints are localized within switch regions23, but
whether there is a common mechanism resulting speci-
ﬁcally in formation of t(11;14), t(14;16) or t(14;20) is
unclear. If Africans display an overall increased risk of
development of t(11;14), for example, one could expect
increased incidence of other malignancies such as mantle
cell lymphoma (MCL) also characterized by t(11;14)(q13;
q32). However, epidemiological studies do not support an
increased incidence of MCL among individuals of African
relative to European descent24,25. In contrast to MM,
where formation of t(11;14) is mediated by errors in class
switch recombination, the t(11;14) in MCL results in
errors in VDJ recombination;26 whether these mechanistic
differences contributes to differences in the predisposition
between Africans and Europeans warrants further
investigation.
The further utilization of ancestry informative markers
for precise characterization of biologic ancestry can help
elucidate the genetic mechanisms of how race contributes
to health disparities, particularly in MM where it is known
that AAs have a 2–3 fold higher incidence of developing
this disease3. Although MM is generally considered a
single disease entity, MM likely represents multiple dis-
eases characterized by distinct, mutually exclusive pri-
mary cytogenetic abnormalities with differences in disease
outcome. The detection of a greater prevalence of t
(11;14), t(14;16) or t(14;20) as the fraction of African
ancestry increases suggests an increased incidence of
speciﬁc cytogenetic subtypes in AAs rather than a global
increase in all subtypes. This observation was only
apparent when we separated our cohort into the most
extreme populations with regard to African ancestry;
individuals with ≥80.0% (n= 120) African ancestry and
individuals with <0.1% African (excluding Asian ancestry)
(n= 235) with the majority of patients (n= 526, 60%) not
included in these extreme populations due to mixed
ancestry. Although many individuals in the US are of
mixed ancestry, ancestral characterization of patient
cohorts is required to fully understand how the role of
human genetic variation associated with ancestry impacts
health disparities. Future studies will include enlarging
our ≥80.0% cohort and increasing the granularity of our
studies with regards to speciﬁc regions within Africa.
Understanding the cause of health disparities in mono-
clonal gammopathies has the potential to provide pre-
viously unrecognized interventions.
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